NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
Introduction of a Differentiated Bispecific Nano ADC Positioned to Compete in Major Global Oncology Markets BOSTON, MA, ...
J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...
The identification of all potential EGFR driver mutations is especially critical for patients with lung adenocarcinoma from East Asia or of Asian descent because of the prevalence of such mutations ...
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 ...
Older adults living with heart failure with preserved ejection fraction (HFpEF) are frequently labeled as having chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results